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Introduction: Parkinson’s disease is the second most common neurodegenerative 
disease. Monoamine oxidase B inhibitors are used in the treatment of this disease 
concomitantly with levodopa or as monotherapy. Several substituted coumarins have 
shown activity as inhibitors of monoamine oxidase B.
Objective: To evaluate the possible antiparkinsonian effects of the coumarin analogue 
FCS005 (3-methyl-7H-furo[3,2-g]chromen-7-one) in mouse models, as well as its inhibitory 
activity towards monoamine oxidases (MAO) and its antioxidant activity. 
Materials and methods: FCS005 was synthesized and the reversal of hypokinesia was 
evaluated in the reserpine and levodopa models. Moreover, in the haloperidol model, its 
anticataleptic effects were evaluated. Additionally, the monoamine oxidase inhibitory activity and 
antioxidant activity of FCS005 were evaluated using in vitro and ex vivo studies, respectively.
Results: FCS005 (100 mg/kg) caused the reversal of hypokinesia in the reserpine and 
levodopa models. This furocoumarin also presented anti-cataleptic effects at the same 
dose. Besides, it showed selective inhibitory activity towards the MAO-B isoform and 
antioxidant activity.
Conclusion: These results attribute interesting properties to the compound FCS005. It 
is important to continue research on this molecule considering that it could be a potential 
antiparkinsonian agent.
Keywords: Parkinson’s disease; monoamine oxidase; coumarins; models, animal; 
reserpine; levodopa; haloperidol; antioxidants. 
El análogo de cumarina 3-metil-7H-furo[3,2-g]cromen-7-ona, un posible agente 
antiparkinsoniano
Introducción. El segundo trastorno neurodegenerativo más común es la enfermedad de 
Parkinson. Los inhibidores de la monoamino oxidasa B se emplean en el tratamiento de 
esta enfermedad en monoterapia o concomitantemente con levodopa. Varios compuestos 
cumarínicos han mostrado actividad como inhibidores de la monoamino oxidasa B.
Objetivo. Evaluar los posibles efectos antiparkinsonianos del análogo de la cumarina 
FCS005 (3-methyl-7H-furo[3,2-g]chromen-7-one) en modelos de ratones, la actividad 
inhibitoria frente a las monoamino oxidasas (MAO) y la actividad antioxidante. 
Materiales y métodos. Se sintetizó la furanocumarina FCS005 y, en los modelos de 
reserpina y levodopa, se evaluó si producía reversión de la hipocinesia; en el modelo 
de haloperidol se evaluaron sus efectos anticatalépticos. Además, se evaluó in vitro la 
actividad inhibidora de MAO y, ex vivo, la actividad antioxidante del compuesto FCS005.
Resultados. El compuesto FCS005 en dosis de 100 mg/kg produjo la remisión de la 
hipocinesia en los modelos de reserpina y de levodopa. Esta furanocumarina presentó 
efectos anticatalépticos con la misma dosis. Además, mostró tener actividad inhibitoria 
selectiva sobre la MAO B, así como efectos antioxidantes.
Conclusión. Los resultados evidenciaron propiedades interesantes del compuesto 
FCS005. Es importante continuar investigando esta molécula porque puede ser un 
potencial agente antiparkinsoniano.
Palabras clave: enfermedad de Parkinson; monoaminooxidasa; cumarinas; modelos 
animales; reserpina; levodopa; haloperidol; antioxidantes.
Parkinson’s disease is the second most common neurodegenerative 
disease after Alzheimer’s. The incidence of the disease ranges from 10 to 
50/100,000 person-years with a prevalence between 100 and 300/100,000 
population (1). Due to the general aging of the population, the number of 
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Parkinson’s disease patients is expected to double by 2030 (1,2). The loss 
of dopamine-secreting neurons within the substantia nigra and the presence 
of Lewy bodies are the major pathological findings in Parkinson’s disease (3) 
while resting tremor, bradykinesia, muscle rigidity, and alterations in balance 
and walking are its main motor symptoms (4,5).
Currently, levodopa (L-dopa) is the most widely used treatment for the 
disease. This symptomatic therapy compensates for the decreased level of 
dopamine (DA). In certain instances (e.g., mild symptoms, tremor as the only or 
most prominent symptom, aged <60 years), other medications as monoamine 
oxidase type B inhibitors may be used initially to avoid levodopa-related motor 
complications (3). The MAO-B inhibitors such as selegiline and rasagiline are a 
valuable adjunct therapy to L- DOPA for Parkinson’s disease (6). These agents 
improve the response to L-dopa in the later stages of the disease and are 
useful in the treatment of disease symptoms in early stages (7).
Several coumarin compounds present activity in the central nervous system 
(CNS). Coumarin (1,2-benzopyrone) obtained from the species Hygrophila 
tyttha Leonard has shown potential effects as an anticonvulsant, anxiolytic, 
and sedative (8). One study indicated that 4-propyl-2H-benzo[h]-chromen-
2-one could have antidepressant effects (9). Different substituted coumarins 
have been synthesized and have shown activity as MAO-B inhibitors (10-
15) and other coumarin derivatives have presented neuroprotective effects 
(16,17), which is important considering that currently it is expected that 
therapeutic alternatives control Parkinson’s disease symptoms and offer an 
approach to slow or stop the progression of neurodegeneration (18). Several 
coumarins have shown antioxidant activity (19,20), which has an interesting 
neuroprotective property as oxidative stress is among the main risk factors 
underlying nigral degeneration. Dopaminergic neurons in this region of the 
CNS are particularly susceptible to oxidative stress (21).
In this study, the coumarin FCS005 (3-methyl-7H-furo[3,2-g]chromen-7-one) 
was synthesized and its possible anti-parkinsonian effects were evaluated.
Materials and methods
Coumarin analogue
FCS005 is a furocoumarin obtained from a 7-hydroxylated coumarin 
following the experimental protocol previously described by Garazd, et al. 
(22). It is an amorphous yellow powder with a melting point at 210-212°C and 
a molecular weight of 200 g/mol. The infrared and 1H/13C magnetic resonance 
spectra led to the elucidation of the structure of 3-methyl-7H-furo[3,2-g]
chromen-7-one (figure 1) reported in the National Center for Biotechnology 
Information database (23). 
Figure 1. Structure of 3-methyl-7H-furo[3,2-g]-chromen-7-one (FCS005)
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Other reagents and drugs used in this investigation were selegiline, 
levodopa, carbidopa and reserpine, all supplied by Sigma-Aldrich. A MAO kit 
was obtained from Molecular Probes™.
Animals
We used male ICR mice six to seven weeks old (25 - 30 g) provided by 
the bioterium of the Departamento de Farmacia, Facultad de Ciencias, at 
Universidad Nacional de Colombia. The animals were kept under standard 
laboratory conditions, 12-hour light-dark cycles, and at room temperature (22 
± 1°C) with food and water available ad libitum.
The effects of FCS005 (50, 100 and 200 mg/kg), selegiline (10 mg/
kg) or the vehicle on motor activity were evaluated at 1.5 and 23.5 h after 
administration in normal mice.
In the reserpine model and l-dopa/carbidopa assays, the locomotor 
activity was evaluated in the open-field test. The open field was a square 
arena divided into 16 squares with surrounding walls to prevent escape. 
Animals were placed individually in the middle of the open field and the 
specific parameter evaluated was the number of cadres traversed during 
5 minutes. The open field was cleaned with a water-alcohol (10%) solution 
before placing the next animal to eliminate possible bias due to odors left by 
previous subjects.
Evaluation of antiparkinsonian effects in the reserpine model
We followed the experimental protocol described by Tadaiesky, et al. (24), 
with some modifications. 
Reserpine 3 mg/kg was administrated intraperitoneally (i.p.) and 30 
minutes later the mice were dosed with selegiline (10 mg/kg), FCS005 (50, 
100 and 200 mg/kg) or vehicle by oral (p.o.) administration. The vehicle was 
a mixture of 15% propylene glycol, 15% glycerol, and enough distilled water 
to make up 100%. Locomotor activity was evaluated at 2 and 24 h after 
reserpine administration. 
Effect of L-dopa/carbidopa and MAO-B inhibitors in mice pretreated with 
reserpine
We evaluated the doses of FCS005 that showed significant differences in 
the reserpine model. The dose of L- dopa and carbidopa that did not cause 
the reversal of hypokinesia was determined in a dose-response relationship 
(data not shown). The mice were dosed with reserpine (3 mg/kg) i.p. 30 min 
before the p.o. administration of FCS005, selegiline or the vehicle. Levodopa 
plus carbidopa were administrated i.p. 30 min later. Locomotor activity was 
evaluated at 2 and 24 h after the administration of reserpine.
Anticataleptic effects and antioxidant activity
Haloperidol was administered to the animals to induce rigidity and akinesia 
(catalepsy) (25,26). Catalepsy was defined as the prolonged maintenance of 
both forepaws in an atypical position on a horizontal bar. 
The animals received haloperidol (3 mg/kg) i.p.; FCS005 (100 mg/kg, 
p.o.), levodopa:carbidopa (400 mg/kg:40 mg/kg; p.o.) or vehicle (p.o) was 
administrated 30 min before. The reversal of catalepsy was evaluated for 2 
min 60 min after the administration of the treatments.
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Antioxidant activity was evaluated ex vivo. Mice were administered daily for 
10 days with the treatments FCS005 (50 mg/kg, p.o.), levodopa:carbidopa (400 
mg/kg:40 mg/kg, p.o.) or vehicle (p.o.) followed by haloperidol (1 mg/kg, i.p.) 
30 min later. Then, the animals were killed by decapitation and the brains were 
removed, washed in 1% KCl, dissected on an ice-cold plate, and homogenized 
in 50 mM Tris-HCl buffer (pH 7.4). Homogenates were centrifuged (10,000 
rpm for 10 min at 4°C). The final supernatant was stored at -20°C. The protein 
content of each sample was determined by the Bradford method.
The index of lipid peroxidation was evaluated following the protocol 
described by Hijova, et al. (27). The brain homogenate (450 µL), 1 mL 
trichloroacetic acid (10%), and 50 µL of 50 mM phosphate buffer (pH 7.4) 
were centrifuged at 1850 xg for 10 min at 4°C; then, 1 mL of thiobarbituric 
acid (0.67%) was added to 1 mL of the supernatant. This mixture was heated 
to 92°C for 30 min and then cooled in an ice bath (4°C) before the absorbance 
was measured at 532 nm. The results were expressed as thiobarbituric acid 
reactive substances (TBARS) in mmol/mL/mg of tissue protein. 
Quantification of protein carbonyl groups was determined by the technique 
of Levine, et al. (28), following the protocol described by Baltacioglu, et al. 
(29). Briefly, 250 µL of 10 mM 2,4-dinitrophenylhydrazine (DNPH) or 250 µL 
of 2 M HCl were added to the brain homogenate (50 µL) for the sample or the 
blank, respectively. The samples were left at room temperature in the dark 
for 1 h and vigorously stirred every 15 min. Then, 500 µL of trichloroacetic 
acid (20%) was added. The samples were kept in an ice bath for 15 min and 
then centrifuged at 11,000 rpm for 5 min. The pellet was washed three times 
with 1 mL of ethyl acetate/ethanol (1:1) solution. After each wash, the sample 
was centrifuged at 3,000 rpm for 7 min. Then, 250 µL of 6 M guanidine 
hydrochloride were added to the pellet to dissolve it and then it was incubated 
at 37°C for 10 min. The absorbance was determined at 360 nm. The content 
of carbonyl groups was calculated based on the molar extinction coefficient of 
DNPH (ε = 22 000 cm-1M-1) and expressed as nmol/mg protein (29).
Assay of human monoamine oxidase (hMAO) inhibitory activity
The effects of FCS005 on hMAO isoform enzymatic activity were evaluated 
using a MAO kit (Molecular Probes™) using the experimental protocol 
previously described by Yáñez, et al. (30). Briefly, adequate amounts of 
recombinant hMAO-A (1.1 mg protein; specific activity: 150 nmol p-tyramine 
oxidized to p-hydroxyphenylacetaldehyde/min/mg protein) or hMAO-B (7.5 
mg protein; specific activity: 22 nmol p-tyramine transformed/min/mg protein) 
were added to 0.1 mL of sodium phosphate buffer (0.05 M, pH 7.4) to obtain 
the same reaction velocity and FCS005 in various concentrations. This mixture 
was incubated for 15 min at 37°C in a flat, black-bottomed 96-well microtest 
plate in a dark fluorimeter chamber. Then, the reaction was started by adding 
(final concentrations) 200 µM Amplex™ Red reagent, 1 U/mL horseradish 
peroxidase, and 1 mM p-tyramine. The production of H2O2 and, consequently, 
of resorufin was quantified at 37°C in a multi-detection microplate fluorescence 
reader (FLX800TM, Bio-Tek Instruments, Inc., Winooski, VT, USA) based on the 
fluorescence generated (emission: 590 nm, excitation: 545 nm) over a 15-min 
period in which the fluorescence increased linearly.
The test drugs were added to solutions containing only the Amplex™ 
Red reagent in a sodium phosphate buffer to determinate the capacity of 
FCS005 or the reference inhibitors to modify the fluorescence generated 
in the reaction mixture due to non-enzymatic inhibition. In the control 
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experiments, the test drugs were replaced with dilutions of the vehicles. In 
addition, the specific fluorescence emission was calculated after subtraction 
of the background activity, which was determined from wells containing all 
components except the hMAO isoforms that were replaced by a sodium 
phosphate buffer solution.
Statistical analysis
Results were expressed as mean ± standard error of the mean (SEM) and 
assessed by a one-way analysis of variance (ANOVA) followed by the Tukey 
test to determine the treatments responsible for the significant differences. 
When the variance was not homogeneous or the data did not show normal 
distribution, the Kruskal-Wallis test was applied. The data on catalepsy were 
processed by a two-way analysis of variance (ANOVA) with the Bonferroni 
post hoc test. The graphical representation and statistical analysis were 
performed using GraphPad Prism (v. 5.03)
Ethical aspects 
All the experimental protocols were evaluated and approved by the ethics 
committee of the Facultad de Ciencias, Universidad Nacional de Colombia 
(Minutes No. 06, October 18, 2011).
Results
Mice not pretreated with reserpine
The compound FCS005 (50 mg/kg) caused a significant decrease in the 
locomotor activity of mice not pretreated with reserpine (figure 2) compared to 
the control group, both at 2 hours (p: 0.023) and at 24 hours (p: 0.003) post 
reserpine administration. 
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Figure 2. Mice not pretreated with reserpine. Effects on motor activity of the animals at 1.5 h (a) 
and 23.5 h (b) after administration of FCS005, selegiline or vehicle (0.1 mL/10 g body weight). 
* p<0.05 compared to the control group (n=7-9)
Antiparkinsonian effects
In the reserpine model, we observed that FCS005 (100 mg/kg) caused 
a reversal of hypokinesia produced by reserpine significantly increasing the 
number of cadres traversed compared to the control at 2 h (p: 0.007) and 24 
h (p: 0.002) (figure 3).
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Effect of L-dopa/carbidopa and MAO-B inhibitors in mice pretreated with 
reserpine
We evaluated the effect of concomitant administration of MAO-B 
inhibitors and L-dopa at low doses. We used the dose 100:10 mg/kg of 
L-dopa:carbidopa given that in the dose-response relationship this dose did 
not lead to the reversal of hypokinesia (data not shown). We evaluated the 
dose of FCS005 (100 mg/kg) that showed the best response in the reserpine 
model. In this assay, FCS005 increased the number of cadres traversed 
showing a statistically significant difference compared to the control at 2 h (p: 
0.038) and 24 h (p: 0.018) (figure 4).
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Figure 3. Reserpine model. Effects of administration of FCS005, selegiline or vehicle (0.1 mL/10 
g body weight) on motor activity of the animals at 2 h (a) and 24 h (b) after administration of 
reserpine. 
* p<0.05 compared to the control group (n=7-9)
Figure 4. Effect of L-dopa/carbidopa and MAO-B inhibitors. Effects of the administration of 
levodopa/carbidopa (100/10 mg/kg) plus FCS005 (100 mg/kg), control (0 mg/kg) or selegiline (10 
mg/kg) on motor activity at 2 h (a) and 24 h (b) after the administration of reserpine. 
* p<0.05 compared to control group (n=7-9)
Anticataleptic effects 
The treatments showed no cataleptic effects at time zero. L-dopa/
carbidopa and FCS005 produced a significant decrease in the total catalepsy 
time using the horizontal bar test at 60 min (p: 0.001) (figure 5).
Antioxidant activity
Protein carbonyl groups and lipid peroxidation levels were lower in brain 
homogenates of mice treated with FCS005 and L-dopa/carbidopa compared 
to the control animals. The animals that did not receive haloperidol (basal 
state) presented lower levels than those of the control and treatments groups 
(p<0.001) (figure 6).
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In vitro inhibition of the A and B isoforms of MAO 
FCS005 presented selective inhibitory activity towards MAO-B. This 
coumarin analogue did not inhibit MAO-A isoform activity at the highest 
concentration tested (100 µM). The reference inhibitors and FCS005 did not 
interfere with the measurements because these drugs did not react directly 
with the Amplex™ Red reagent. The corresponding IC50 values and the 
selectivity index [IC50 (hMAO-A)]/[IC50 (hMAO-B)] are shown in table 1.
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Figure 6. Antioxidant activity. Effect of FCS005 (50 mg/kg), control (0 mg/kg) or levodopa/
carbidopa (400/40 mg/kg) on (a) lipid peroxidation and (b) the oxidation of carbonyl groups of 
proteins in brain homogenates of mice treated with haloperidol (1 mg/kg) for 10 days
* p<0.05 compared to the control group (n=8)
Figure 5. Anti-cataleptic effects. Catalepsy in mice was assessed using the horizontal bar test. 
Effects of administration of levodopa/carbidopa (400/40 mg/kg), FCS005 (100 mg/kg) or control 
(0 mg/kg) on catalepsy induced by haloperidol (3 mg/kg) at 60 min 
* p<0.05 compared to the control group (n=8)
Compounds hMAO-A (IC50) hMAO-B (IC50) Selectivity index
b
FCS005
Clorgiline
Selegiline
Iproniazide
*
4.46 ± 0.32 nM
67.25 ± 1.02 µM
6.56 ± 0.76 µM
41.63 ± 2.79 µM
61.35 ± 1.13 µM
19.60 ± 0.86 nM
  7.54 ± 0.36 µM
> 2.4c
0.000073
3.431
0.87
Table 1. In vitro inhibitory activities of reference compounds and FCS005 towards hMAO-A and 
hMAO-B isoformsa 
a Each IC50 value is the mean ± S.E.M. from five experiments (n=5).
b hMAO-B selectivity ratios [IC50 (hMAO-A)]/[IC50 (hMAO-B)] for inhibitory effects of FCS005 compound and 
reference inhibitors
c Values obtained under the assumption that the corresponding IC50 against hMAO-A is the highest 
concentration tested (100 µM)
* Inactive at 100 µM (highest concentration tested) 
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Discussion 
The antiparkinsonian activity of FCS005 was evaluated in mice using the 
reserpine model. The effect of reserpine on spontaneous locomotor activity 
is frequently used as a model of motor disturbances in Parkinson’s disease 
(24,31,32,33). Some drugs currently on the market were tested in this model 
suggesting it has predictive validity (24,33).
Hypokinesia occurs in mice because reserpine blocks the vesicular 
monoamine transporter and produces a profound and lasting decrease 
in catecholamines, a situation that results in the depletion of DA in all 
dopaminergic nerve terminals including the nigrostriatal pathway (14,18). 
FCS005 (100 mg/kg) caused the significant reversal of hypokinesia in the 
reserpine and levodopa models. This could be explained by the fact that 
the synthetic coumarin FCS005 showed selective inhibitory activity against 
hMAO-B in vitro. MAO inhibitors reduce the enzymatic degradation of 
dopamine by MAO, thus leading to an increase in monoamines and striatal 
dopaminergic activity and improving motor symptoms in Parkinson´s disease 
(34,35). Dopamine acts on postsynaptic D1 and D2 receptors to control 
movement (36). The selective inhibitory activity on MAO type B prolongs the 
activity of both endogenously and exogenously derived dopamine, which 
represents an option either as monotherapy in early Parkinson’s disease or 
as adjuvant therapy in patients treated with levodopa when they experience 
motor complications (35). Selegiline and rasagiline, selective inhibitors of 
MAO-B, are used in clinical practice to improve the response to L-dopa at 
later stages of the disease (7).
FCS005 at a dose of 50 mg/kg led to a significant decrease in motor 
activity in mice not treated with reserpine. However, this did not affect the 
evaluation in the models of reserpine and levodopa where the reversal of 
hypokinesia was evaluated. On the other hand, the decrease in motor activity 
at 24 h with all treatments could be attributed to habituation that occurs due to 
repeated exposure to the open field (37,38).
The coumarin analogue FCS005 showed anti-cataleptic effects in the 
haloperidol model. The animals presented catalepsy and muscular rigidity 
because haloperidol blocks nigrostriatal dopamine transmission (39,40). These 
symptoms may be analogous to the inability of Parkinson’s disease patients to 
initiate movements (40). FSC005 did not show any cataleptic effects.
Some studies have shown that chronic administration of haloperidol 
induces increased levels of lipid peroxidation and decreased levels of 
antioxidant enzymes and reduced glutathione (41,42). Besides, the results 
of Martins, et al. (43) showed that TBARS increased in the striatum after the 
administration of haloperidol in repeated doses. In this study, an increase in 
the TBARS concentration was also observed, possibly because dopamine 
receptors were blocked by haloperidol leading to an increase in dopamine 
and, therefore, to the production of hydrogen peroxide and other toxic 
metabolites of dopamine (44,45). Hydrogen peroxide in the presence of 
Fe2+ and Cu2+ produces hydroxyl radical capable of oxidizing almost any 
cell structure, which leads to neurodegeneration and contributes to the 
development of pathologies (46). Antioxidants, free radical scavengers, 
and similar drugs have been potentially used in therapeutic development 
to prevent Parkinson’s disease. The results of some authors suggest that 
coumarins and flavonoids can directly capture the reactive oxygen species 
(47). FCS005 had a significant protective effect against oxidative stress, 
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probably because MAO-B inhibitors can reduce oxidative stress by reducing 
H2O2 production, thus acting as neuroprotective agents (34).
FCS005 (3-methyl-7H-furo[3,2-g]-chromen-7-one) is a furocoumarin with a 
structure similar to that of psoralen, which is isolated from the plant Psoralea 
corylifolia L. and is used traditionally to treat ageing. Psoralen was demonstrated 
to exhibit in vitro inhibitory actions on MAO activities in rat brain mitochondria, 
preferentially inhibiting MAO-A activity over MAO-B activity (48) while FCS005 
exhibited selective MAO-B inhibitory activity, which could be attributed to the 
substitution at position 3; this is the only difference between the two structures.
In conclusion, the coumarin analogue FCS005 synthesized in this 
research led to the reversal of hypokinesia in the reserpine and levodopa 
models of Parkinson’s disease and demonstrated anticataleptic effects. 
Besides, it showed selective inhibitory activity towards MAO-B, as well as 
antioxidant activity. These results attribute interesting properties to FCS005 
supporting further investigations on its potential as an antiparkinsonian agent 
including the use of models useful to asses not only the control of symptoms 
but, especially, neuroprotection.
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